@article {P{\"o}lcher555-560, author = {Martin P{\"o}lcher and Nicolaus Friedrichs and Christian Rudlowski and Rolf Fimmers and Mignon-Denise Keyver-Paik and Kirsten K{\"u}bler and Axel Sauerwald and Reinhard B{\"u}ttner and Walther Kuhn and Michael Braun}, title = {Changes in Ki-67 Labeling Indices During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Are Associated With Survival}, volume = {20}, number = {4}, pages = {555-560--555-560}, year = {2010}, doi = {10.1111/IGC.0b013e3181c104c0}, publisher = {BMJ Specialist Journals}, abstract = {Objective: To evaluate changes in Ki-67 expression during neoadjuvant chemotherapy (NACT) in advanced ovarian cancer.Materials and Methods: Patients with International Federation of Gynecology and Obstetrics stage IIIC or IV and large-volume ascites were treated with NACT within a phase 2 trial. The expression of Ki-67 was evaluated by immunohistochemistry on paraffin-embedded tissue samples and classified by percentage of stained cells. Survival curves were plotted using the Kaplan-Meier method.Results: Comparison of 40 individual paired results from pretreatment and posttreatment samples revealed a median difference of -0.11 in the Ki-67 index (95\% confidence interval, -0.20 to -0.01; P = 0.005, signed rank test). Univariate analysis identified a high Ki-67 index as well as an increasing Ki-67 index after NACT as significant prognostic markers for progression-free survival (P = 0.004 and P = 0.001; log-rank test). Six of 12 patients with an increased Ki-67 index after NACT developed recurrence within 6 months after therapy.Conclusions: Changes of the Ki-67 index during NACT are associated with progression-free survival. If confirmed in prospective trials, an increasing Ki-67 index during preoperative treatment may serve as an indicator for resistance to chemotherapy.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/20/4/555-560}, eprint = {https://ijgc.bmj.com/content/20/4/555-560.full.pdf}, journal = {International Journal of Gynecologic Cancer} }